Joseph W. Laplume Sells 4,400 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Charles River Laboratories International Stock Up 0.5 %

NYSE CRL opened at $163.11 on Monday. The stock’s 50-day moving average price is $172.84 and its 200-day moving average price is $188.00. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $275.00. The company has a market capitalization of $8.34 billion, a P/E ratio of 1,087.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same quarter last year, the company earned $2.46 earnings per share. The business’s revenue for the quarter was down 1.1% compared to the same quarter last year. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRL has been the topic of several recent analyst reports. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research report on Monday, November 18th. JPMorgan Chase & Co. dropped their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday. TD Cowen increased their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Finally, Morgan Stanley dropped their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and an average target price of $195.71.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Empirical Finance LLC raised its stake in shares of Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after buying an additional 53 shares during the period. Fiduciary Financial Group LLC raised its stake in Charles River Laboratories International by 3.9% during the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock valued at $310,000 after purchasing an additional 63 shares during the period. Pinnacle Bancorp Inc. raised its stake in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the period. M&T Bank Corp raised its stake in Charles River Laboratories International by 3.4% during the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock valued at $394,000 after purchasing an additional 66 shares during the period. Finally, Cornerstone Investment Partners LLC raised its stake in Charles River Laboratories International by 3.7% during the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock valued at $358,000 after purchasing an additional 69 shares during the period. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).